Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to "Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures".

ACS pharmacology & translational science·2026
Same author

Correction to "Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures".

ACS pharmacology & translational science·2026
Same author

Preclinical characterization of pharmacokinetics, enzyme occupancy, and pharmacodynamics of soticlestat (TAK-935), a novel cholesterol 24-hydroxylase inhibitor.

The Journal of pharmacology and experimental therapeutics·2026
Same author

Significance of Total Colonoscopy Based on the Outcome of Advanced Colorectal Cancer in Older Individuals.

Asian Pacific journal of cancer prevention : APJCP·2026
Same author

Comprehensive Analysis of Clinically Discontinued Compounds Using an In Vitro Secondary Pharmacology Panel to Predict Potential Safety Risks during Drug Development.

ACS pharmacology & translational science·2025
Same author

Factors Influencing Resection Time in Endoscopic Submucosal Dissection for Rectal Neuroendocrine Tumors.

DEN open·2025

Related Experiment Video

Updated: Jul 14, 2026

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

A robust, target-driven, cell-based assay for checkpoint kinase 1 inhibitors.

Tsuyoshi Ish1, Hiroshi Sootome, Alastair J King

  • 1GlaxoSmithKline K.K., Tsukuba-shi Ibaraki, Japan. hiroshi_sootome@merck.com

Journal of Biomolecular Screening
|May 23, 2007
PubMed
Summary

A novel cell-based assay was developed to specifically detect Checkpoint kinase 1 (Chk1) activity. This highly sensitive platform enables efficient discovery of Chk1 inhibitors for cancer therapy.

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Experiment Videos

Last Updated: Jul 14, 2026

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Checkpoint kinase 1 (Chk1) is crucial for DNA damage response and a key target in cancer therapy.
  • Developing specific assays for Chk1 is essential for identifying novel cancer treatments.

Purpose of the Study:

  • To establish a Chk1-specific cell-based assay for high-throughput screening.
  • To validate the assay's performance and utility in structure-activity relationship studies.

Main Methods:

  • Engineered stable cell clones expressing an inducible Chk1 kinase domain fused to p53.
  • Confirmed Chk1 specificity through phosphorylation of p53 at Ser-15.
  • Evaluated assay performance using Z' factor values for high-throughput screening suitability.

Main Results:

  • The inducible system successfully demonstrated Chk1-specific phosphorylation of the p53 fusion protein.
  • The assay achieved high performance with Z' factor values exceeding 0.77.
  • Structure-activity relationship data for Chk1 inhibitors were generated within the cellular context.

Conclusions:

  • A novel, sensitive cell-based assay for Chk1 activity has been successfully established.
  • This platform is suitable for high-throughput screening and facilitates Chk1 inhibitor discovery.
  • The assay provides a valuable tool for advancing cancer therapeutic strategies targeting Chk1.